{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:53:10Z","timestamp":1758815590979},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1007\/s11926-008-0057-y","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T07:40:07Z","timestamp":1224056407000},"page":"349-355","source":"Crossref","is-referenced-by-count":16,"title":["Beh\u00e7et\u2019s disease: Recent advances in early diagnosis and effective treatment"],"prefix":"10.1007","volume":"10","author":[{"given":"Kenneth T.","family":"Calamia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phaedon G.","family":"Kaklamanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,16]]},"reference":[{"issue":"3Suppl50","key":"57_CR1","first-page":"A12","volume":"26","author":"K. Calamia","year":"2008","unstructured":"Calamia K, Wilson F, Icen M, et al.: Epidemiology and clinical characteristics of Behcet\u2019s disease in the United States: A population-based study [abstract]. Clin Exp Rheumatol 2008, 26(3 Suppl 50):A12.","journal-title":"Clin Exp Rheumatol"},{"issue":"3Suppl50","key":"57_CR2","first-page":"A11","volume":"26","author":"F. Shahram","year":"2008","unstructured":"Shahram F, Nadji A, Chams H, et al.: Epidemiological data from the Iran Registry of Behcet\u2019s Disease, report of 6,128 cases [abstract]. Clin Exp Rheumatol 2008, 26(3 Suppl 50):A11.","journal-title":"Clin Exp Rheumatol"},{"key":"57_CR3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10384-007-0473-y","volume":"51","author":"N. Mizuki","year":"2007","unstructured":"Mizuki N, Meguro A, Tohnai I, et al.: Association of major histocompatibility complex class I chain-related gene A and HLA-B alleles with Behcet\u2019s disease in Turkey. Jpn J Ophthalmol 2007, 51:431\u2013436.","journal-title":"Jpn J Ophthalmol"},{"key":"57_CR4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/1529-0131(200101)44:1<239::AID-ANR31>3.0.CO;2-X","volume":"44","author":"A. Gul","year":"2001","unstructured":"Gul A, Hajeer AH, Worthington J, et al.: Evidence for linkage of the HLA-B locus in Behcet\u2019s disease, obtained using the transmission disequilibrium test. Arthritis Rheum 2001, 44:239\u2013240.","journal-title":"Arthritis Rheum"},{"issue":"3Suppl50","key":"57_CR5","first-page":"A8","volume":"26","author":"A. Mahr","year":"2008","unstructured":"Mahr A, de Menthon M, LaValley M, Guillevin L: HLA-B5 (1) and risk of Behcet\u2019s disease: a meta-analysis of genetic association studies [abstract]. Clin Exp Rheumatol 2008, 26(3 Suppl 50):A8.","journal-title":"Clin Exp Rheumatol"},{"key":"57_CR6","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/1529-0131(200111)44:11<2693::AID-ART449>3.0.CO;2-M","volume":"44","author":"A. Gul","year":"2001","unstructured":"Gul A, Hajeer AH, Worthington J, et al.: Linkage mapping of a novel susceptibility locus for Behcet\u2019s disease to chromosome 6p22\u201323. Arthritis Rheum 2001, 44:2693\u20132696.","journal-title":"Arthritis Rheum"},{"key":"57_CR7","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/art.21060","volume":"52","author":"J. Karasneh","year":"2005","unstructured":"Karasneh J, Gul A, Ollier WE, et al.: Whole-genome screening for susceptibility genes in multicase families with Behcet\u2019s disease. Arthritis Rheum 2005, 52:1836\u20131842.","journal-title":"Arthritis Rheum"},{"key":"57_CR8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1568010053622894","volume":"4","author":"A. Gul","year":"2005","unstructured":"Gul A: Behcet\u2019s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 2005, 4:81\u201383.","journal-title":"Curr Drug Targets Inflamm Allergy"},{"issue":"4Suppl30","key":"57_CR9","first-page":"S35","volume":"21","author":"P. Atagunduz","year":"2003","unstructured":"Atagunduz P, Ergun T, Direskeneli H: MEFV mutations are increased in Behcet\u2019s disease (BD) and are associated with vascular involvement. Clin Exp Rheumatol 2003, 21(4 Suppl 30):S35\u2013S37.","journal-title":"Clin Exp Rheumatol"},{"key":"57_CR10","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1136\/ard.2006.068841","volume":"66","author":"I. Kone-Paut","year":"2007","unstructured":"Kone-Paut I, Sanchez E, Le Quellec A, et al.: Autoinflammatory gene mutations in Behcet\u2019s disease. Ann Rheum Dis 2007, 66:832\u2013834.","journal-title":"Ann Rheum Dis"},{"key":"57_CR11","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/rheumatology\/kel329","volume":"45","author":"H. Direskeneli","year":"2006","unstructured":"Direskeneli H: Autoimmunity vs autoinflammation in Behcet\u2019s disease: do we oversimplify a complex disorder? Rheumatology (Oxford) 2006, 45:1461\u20131465.","journal-title":"Rheumatology (Oxford)"},{"key":"57_CR12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/BOR.0b013e3282f1bf4b","volume":"20","author":"J.G. Ryan","year":"2008","unstructured":"Ryan JG, Goldbach-Mansky R: The spectrum of autoin-flammatory diseases: recent bench to bedside observations. Curr Opin Rheumatol 2008, 20:66\u201375.","journal-title":"Curr Opin Rheumatol"},{"key":"57_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2006.01863.x","volume":"21","author":"A. Kalayciyan","year":"2007","unstructured":"Kalayciyan A, Zouboulis C: An update on Behcet\u2019s disease. J Eur Acad Dermatol Venereol 2007, 21:1\u201310.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4Suppl45","key":"57_CR14","first-page":"S27","volume":"25","author":"G. Mumcu","year":"2007","unstructured":"Mumcu G, Inanc N, Yavuz S, Direskeneli H: The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behcet\u2019s disease. Clin Exp Rheumatol 2007, 25(4 Suppl 45):S27\u2013S33.","journal-title":"Clin Exp Rheumatol"},{"key":"57_CR15","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3349\/ymj.2007.48.4.601","volume":"48","author":"S.W. Yi","year":"2007","unstructured":"Yi SW, Kim EH, Kang HY, et al.: Erythema nodosum: clinicopathologic correlations and their use in differential diagnosis. Yonsei Med J 2007, 48:601\u2013608.","journal-title":"Yonsei Med J"},{"key":"57_CR16","first-page":"146","volume":"16","author":"T. Ilknur","year":"2006","unstructured":"Ilknur T, Pabuccuoglu U, Akin C, et al.: Histopathologic and direct immunofluorescence findings of the papulopustular lesions in Behcet\u2019s disease. Eur J Dermatol 2006, 16:146\u2013150.","journal-title":"Eur J Dermatol"},{"key":"57_CR17","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-4632.2006.02797.x","volume":"45","author":"A. Boyvat","year":"2006","unstructured":"Boyvat A, Heper AO, Kocyigit P, et al.: Can specific vessel-based papulopustular lesions of Behcet\u2019s disease be differentiated from nonspecific follicular-based lesions clinically? Int J Dermatol 2006, 45:814\u2013818.","journal-title":"Int J Dermatol"},{"key":"57_CR18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-4632.2008.03568.x","volume":"47","author":"M. Ozdemir","year":"2008","unstructured":"Ozdemir M, Bodur S, Engin B, Baysal I: Evaluation of application of multiple needle pricks on the pathergy reaction. Int J Dermatol 2008, 47:335\u2013338.","journal-title":"Int J Dermatol"},{"issue":"3Suppl50","key":"57_CR19","first-page":"A3","volume":"26","author":"F. Davatchi","year":"2008","unstructured":"Davatchi F, Chams-Davatchi C, Shahram F, et al.: Changes in incidence of pathergy phenomenon in Behcet\u2019s disease over time [abstract]. Clin Exp Rheumatol 2008, 26(3 Suppl 50):A3.","journal-title":"Clin Exp Rheumatol"},{"key":"57_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/01.rhu.0000255693.75314.fd","volume":"13","author":"A. Pandrea","year":"2007","unstructured":"Pandrea A, Rudinskaya A, Klein B, Krebs T: What does it take to diagnose Behcet disease?. J Clin Rheumatol 2007, 13:31\u201334.","journal-title":"J Clin Rheumatol"},{"key":"57_CR21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11926-006-0016-4","volume":"8","author":"E. Diri","year":"2006","unstructured":"Diri E, Espinoza LR: Neuro-Behcet\u2019s syndrome: differential diagnosis and management. Curr Rheumatol Rep 2006, 8:317\u2013322.","journal-title":"Curr Rheumatol Rep"},{"key":"57_CR22","first-page":"1078","volume":"335","author":"International Study Group for Beh\u00e7et\u2019s Disease","year":"1990","unstructured":"International Study Group for Beh\u00e7et\u2019s Disease: Criteria for diagnosis of Behcet\u2019s disease. Lancet 1990, 335:1078\u20131080.","journal-title":"Lancet"},{"key":"57_CR23","first-page":"1620","volume-title":"Fitzpatrick\u2019s Dermatology in General Medicine","author":"C.C. Zouboulis","year":"2008","unstructured":"Zouboulis CC: Adamantiades-Beh\u00e7et disease. In Fitzpatrick\u2019s Dermatology in General Medicine, 7th edn. Edited by Wolff K, Goldsmith L, Katz S, et al.: New York: The McGraw-Hill Companies, Inc.; 2008: 1620\u20131626.","edition":"7th edn."},{"key":"57_CR24","first-page":"2511","volume":"26","author":"M. Schirmer","year":"1999","unstructured":"Schirmer M, Calamia KT, O\u2019Duffy D: Is there a place for large-vessel disease in the diagnostic criteria for Beh\u00e7et\u2019s disease. J Rheumatol 1999, 26:2511\u20132512.","journal-title":"J Rheumatol"},{"key":"57_CR25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"Wegener\u2019s Granulomatosis Etanercept Trial","year":"2005","unstructured":"Wegener\u2019s Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener\u2019s granulomatosis. N Engl J Med 2005, 352:351\u2013361.","journal-title":"N Engl J Med"},{"key":"57_CR26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","volume":"146","author":"G.S. Hoffman","year":"2007","unstructured":"Hoffman GS, Cid MC, Rendt-Zagar KE, et al.: Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007, 146:621\u2013630.","journal-title":"Ann Intern Med"},{"key":"57_CR27","first-page":"98","volume":"32","author":"M. Melikoglu","year":"2005","unstructured":"Melikoglu M, Fresko I, Mat C, et al.: Short-term trial of etanercept in Behcet\u2019s disease: a double blind, placebo controlled study. J Rheumatol 2005, 32:98\u2013105.","journal-title":"J Rheumatol"},{"key":"57_CR28","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","volume":"46","author":"P.P. Sfikakis","year":"2007","unstructured":"Sfikakis PP, Markomichelakis N, Alpsoy E, et al.: Anti-TNF therapy in the management of Behcet\u2019s disease\u2014review and basis for recommendations. Rheumatology (Oxford) 2007, 46:736\u2013741.","journal-title":"Rheumatology (Oxford)"},{"key":"57_CR29","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1196\/annals.1423.050","volume":"1110","author":"S. Tognon","year":"2007","unstructured":"Tognon S, Graziani G, Marcolongo R: Anti-TNF-alpha therapy in seven patients with Behcet\u2019s uveitis: advantages and controversial aspects. Ann N Y Acad Sci 2007, 1110:474\u2013484.","journal-title":"Ann N Y Acad Sci"},{"key":"57_CR30","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","volume":"46","author":"L. Niccoli","year":"2007","unstructured":"Niccoli L, Nannini C, Benucci M, et al.: Long-term efficacy of infliximab in refractory posterior uveitis of Behcet\u2019s disease: a 24-month follow-up study. Rheumatology (Oxford) 2007, 46:1161\u20131164.","journal-title":"Rheumatology (Oxford)"},{"key":"57_CR31","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/jop.2007.0015","volume":"23","author":"S. Tuncer","year":"2007","unstructured":"Tuncer S, Yilmaz S, Urgancioglu M, Tugal-Tutkun I: Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behcet disease. J Ocul Pharmacol Ther 2007, 23:395\u2013401.","journal-title":"J Ocul Pharmacol Ther"},{"key":"57_CR32","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00417-006-0514-0","volume":"245","author":"L.S. Atmaca","year":"2007","unstructured":"Atmaca LS, Yalcindag FN, Ozdemir O: Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behcet\u2019s disease. Graefes Arch Clin Exp Ophthalmol 2007, 245:451\u2013456.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"57_CR33","unstructured":"Hatemi G, Silman A, Bang D, et al.: EULAR recommendations for the management of Behcet\u2019s disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2008, (Jan 31 Epub ahead of print)."},{"key":"57_CR34","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/bjo.82.5.488","volume":"82","author":"I. Kotter","year":"1998","unstructured":"Kotter I, Eckstein AK, Stubiger N, Zierhut M: Treatment of ocular symptoms of Behcet\u2019s disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 1998, 82:488\u2013494.","journal-title":"Br J Ophthalmol"},{"key":"57_CR35","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","volume":"87","author":"I. K\u00f6tter","year":"2003","unstructured":"K\u00f6tter I, Zierhut M, Eckstein AK, et al.: Human recombinant interferon alfa-2a for the treatment of Beh\u00e7et\u2019s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003, 87:423\u2013431.","journal-title":"Br J Ophthalmol"},{"key":"57_CR36","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","volume":"244","author":"I. Tugal-Tutkun","year":"2006","unstructured":"Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M: Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol 2006, 244:1692\u20131695.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"57_CR37","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bjo.2006.101550","volume":"91","author":"B. Bodaghi","year":"2007","unstructured":"Bodaghi B, Gendron G, Wechsler B, et al.: Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007, 91:335\u2013339.","journal-title":"Br J Ophthalmol"},{"key":"57_CR38","first-page":"896","volume":"35","author":"L. Krause","year":"2008","unstructured":"Krause L, Altenburg A, Pleyer U, et al.: Longterm visual prognosis of patients with ocular Adamantiades-Behcet\u2019s disease treated with interferon-alpha-2a. J Rheumatol 2008, 35:896\u2013903.","journal-title":"J Rheumatol"},{"key":"57_CR39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.semarthrit.2003.09.005","volume":"33","author":"I. Kotter","year":"2004","unstructured":"Kotter I, Vonthein R, Zierhut M, et al.: Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. Semin Arthritis Rheum 2004, 33:311\u2013319.","journal-title":"Semin Arthritis Rheum"},{"key":"57_CR40","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","volume":"33","author":"I. Kotter","year":"2004","unstructured":"Kotter I, Gunaydin I, Zierhut M, Stubiger N: The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 2004, 33:320\u2013335.","journal-title":"Semin Arthritis Rheum"},{"key":"57_CR41","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s10067-005-0070-8","volume":"25","author":"I. Kotter","year":"2006","unstructured":"Kotter I, Gunaydin I, Batra M, et al.: CNS involvement occurs more frequently in patients with Behcet\u2019s disease under cyclosporin A (CSA) than under other medications\u2014results of a retrospective analysis of 117 cases. Clin Rheumatol 2006, 25:482\u2013486.","journal-title":"Clin Rheumatol"},{"key":"57_CR42","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00535-007-2090-4","volume":"42","author":"K. Kobayashi","year":"2007","unstructured":"Kobayashi K, Ueno F, Bito S, et al.: Development of consensus statements for the diagnosis and management of intestinal Behcet\u2019s disease using a modified Delphi approach. J Gastroenterol 2007, 42:737\u2013745.","journal-title":"J Gastroenterol"},{"key":"57_CR43","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/BF02235590","volume":"43","author":"I.J. Choi","year":"2000","unstructured":"Choi IJ, Kim JS, Cha SD, et al.: Long-term clinical course and prognostic factors in intestinal Beh\u00e7t\u2019s disease. Dis Colon Rectum 2000, 43:692\u2013700.","journal-title":"Dis Colon Rectum"},{"key":"57_CR44","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s11605-006-0031-9","volume":"11","author":"S.J. Chou","year":"2007","unstructured":"Chou SJ, Chen VT, Jan HC, et al.: Intestinal perforations in Behcet\u2019s disease. J Gastrointest Surg 2007, 11:508\u2013514.","journal-title":"J Gastrointest Surg"},{"key":"57_CR45","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s10350-006-0706-z","volume":"49","author":"C.H. Choi","year":"2006","unstructured":"Choi CH, Kim TI, Kim BC, et al.: Anti-Saccharomyces cerevisiae antibody in intestinal Behcet\u2019s disease patients: relation to clinical course. Dis Colon Rectum 2006, 49:1849\u20131859.","journal-title":"Dis Colon Rectum"},{"issue":"5Suppl42","key":"57_CR46","first-page":"S87","volume":"24","author":"A. Monselise","year":"2006","unstructured":"Monselise A, Weinberger A, Monselise Y, et al.: Anti-Saccharomyces cerevisiae antibodies in Behcet\u2019s disease\u2014a familial study. Clin Exp Rheumatol 2006, 24(5 Suppl 42):S87\u2013S90.","journal-title":"Clin Exp Rheumatol"},{"key":"57_CR47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10067-007-0685-z","volume":"27","author":"J.K. Ahn","year":"2008","unstructured":"Ahn JK, Lee YS, Jeon CH, et al.: Treatment of venous thrombosis associated with Behcet\u2019s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008, 27:201\u2013205.","journal-title":"Clin Rheumatol"},{"key":"57_CR48","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10067-007-0805-9","volume":"27","author":"C. Korkmaz","year":"2008","unstructured":"Korkmaz C: Is anticoagulation unnecessary in Behcet\u2019s disease with deep venous thrombosis? Clin Rheumatol 2008, 27:405\u2013406.","journal-title":"Clin Rheumatol"},{"key":"57_CR49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/art.23345","volume":"59","author":"N. Pipitone","year":"2008","unstructured":"Pipitone N, Olivieri I, Padula A, et al.: Infliximab for the treatment of neuro-Behcet\u2019s disease: a case series and review of the literature. Arthritis Rheum 2008, 59:285\u2013290.","journal-title":"Arthritis Rheum"},{"key":"57_CR50","doi-asserted-by":"crossref","unstructured":"Kuemmerle-Deschner JB, Tzaribachev N, Deuter C, et al.: Interferon-{alpha}\u2014a new therapeutic option in refractory juvenile Behcet\u2019s disease with CNS involvement. Rheumatology (Oxford) 2008 (in press).","DOI":"10.1093\/rheumatology\/ken172"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-008-0057-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-008-0057-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-008-0057-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:49:50Z","timestamp":1559436590000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-008-0057-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["57"],"URL":"https:\/\/doi.org\/10.1007\/s11926-008-0057-y","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}